Jounce Therapeutics Announces Presentation at Society for Immunotherapy of Cancer’s 30th Annual Meeting

CAMBRIDGE, Mass.--()--Jounce Therapeutics, Inc., an immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients, today announced that Michael Briskin, Ph.D., vice president of research, will present an overview of Jounce’s lead Inducible T cell CO-Stimulator (ICOS) program at the Society for Immunotherapy of Cancer’s 30th Annual Meeting. Dr. Briskin will discuss insights into how the company’s translational science platform aims to prioritize indications and implement patient selection in its clinical trials.

The presentation entitled, “Efficacy of Anti-ICOS Agonist Monoclonal Antibodies in Preclinical Models Provides a Rationale for Clinical Development as a Cancer Immunotherapeutic”, will take place on Saturday, November 7, 2015 from 12:30-12:45 p.m. ET. The conference is being held November 4 – 8, 2015 at the Gaylord National Hotel & Convention Center in National Harbor, Md.

About Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights to prioritize targets and identify related biomarkers to match the right therapy to the right patients, which may also lead to shortened development timelines. The company is advancing programs that leverage contributions from its world-class founders as well as knowledge acquired from Jounce’s translational science platform to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.

Contacts

Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com

Release Summary

Jounce Therapeutics Announces Presentation at Society for Immunotherapy of Cancer’s 30th Annual Meeting.

Contacts

Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com